Paradigm Biopharmaceuticals Statistics
Want to see AU:PAR full AI Analyst Report?
Paradigm Biopharmaceuticals (PAR) Stock Statistics & Valuation Metrics
Total Valuation
Paradigm Biopharmaceuticals has a market cap or net worth of AUD 153.48M. The enterprise value is AUD 48.90M.
- Market Cap
- AUD 153.48M
- Enterprise Value
- AUD 48.90M
Share Statistics
Paradigm Biopharmaceuticals has 626,433,350 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 626,433,350
- Owned by Insiders
- 3.58%
- Owned by Institutions
- <0.01%
Financial Efficiency
Paradigm Biopharmaceuticals’s return on equity (ROE) is -16.23 and return on invested capital (ROIC) is -484.07%.
- Return on Equity (ROE)
- -16.23
- Return on Assets (ROA)
- -1.84
- Return on Invested Capital (ROIC)
- -484.07%
- Return on Capital Employed (ROCE)
- -15.39
- Revenue Per Employee
- 6,679.167
- Profits Per Employee
- -4.69M
- Employee Count
- 12
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Paradigm Biopharmaceuticals is -1.61. Paradigm Biopharmaceuticals’s PEG ratio is 0.02.
- PE Ratio
- -1.61
- PS Ratio
- 1831.58
- PB Ratio
- 24.31
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- -1.93
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, Paradigm Biopharmaceuticals had revenue of 80.15K and earned -56.33M in profits. Earnings per share was -0.15.
- Revenue
- 80.15K
- Gross Profit
- -82.37K
- Operating Income
- -61.11M
- Pretax Income
- -63.95M
- Net Income
- -56.33M
- EBITDA
- -60.96M
- Earnings Per Share (EPS)
- -0.15
Cash Flow
In the last 12 months, operating cash flow was -43.69M and capital expenditures 43.69M, giving a free cash flow of 0 billion.
- Operating Cash Flow
- -43.69M
- Free Cash Flow
- 0
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Paradigm Biopharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- -66.76%
Stock Price Statistics
- Beta
- 2.29
- 52-Week Price Change
- -32.88%
- 50-Day Moving Average
- 0.25
- 200-Day Moving Average
- 0.22
- Relative Strength Index (RSI)
- 56.01
- Average Volume (3m)
- 3.39M
Important Dates
Paradigm Biopharmaceuticals upcoming earnings date is Feb 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 28, 2026
- Next Earnings Date
- Feb 24, 2027
- Ex-Dividend Date
- ―
Financial Position
Paradigm Biopharmaceuticals as a current ratio of 1.10, with Debt / Equity ratio of 216.37%
- Current Ratio
- 1.10
- Quick Ratio
- 1.10
- Debt to Market Cap
- 0.12
- Net Debt to EBITDA
- 0.13
- Interest Coverage Ratio
- -24.83
Taxes
In the past 12 months, Paradigm Biopharmaceuticals has paid -7.62M in taxes.
- Income Tax
- -7.62M
- Effective Tax Rate
- 0.12
Enterprise Valuation
Paradigm Biopharmaceuticals EV to EBITDA ratio is -2.28, with an EV/FCF ratio of 0.00.
- EV to Sales
- 1733.48
- EV to EBITDA
- -2.28
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- -3.18
Balance Sheet
Paradigm Biopharmaceuticals has AUD 15.44M in cash and marketable securities with AUD 7.51M in debt, giving a net cash position of AUD 7.93M billion.
- Cash & Marketable Securities
- AUD 15.44M
- Total Debt
- AUD 7.51M
- Net Cash
- AUD 7.93M
- Net Cash Per Share
- AUD 0.01
- Tangible Book Value Per Share
- AUD 0.01
Margins
Gross margin is -102.76%, with operating margin of -76246.47%, and net profit margin of -70282.28%.
- Gross Margin
- -102.76%
- Operating Margin
- -76246.47%
- Pretax Margin
- -79790.11%
- Net Profit Margin
- -70282.28%
- EBITDA Margin
- -76058.84%
- EBIT Margin
- -76246.47%
Analyst Forecast
The average price target for Paradigm Biopharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 53.78%
- EPS Growth Forecast
- -206.24%
Scores
- Smart Score
- 1
- AI Score
- 47
